Adaptive radiotherapy in lung cancer: dosimetric benefits and clinical outcome.
暂无分享,去创建一个
S. Goyal | T. Kataria | D. Gupta | S. Bisht | N. Karthikeyan | L. Pushpan | A. Abhishek | H. Govardhan | V. Kumar | K. Sharma | S. Jain | T. Basu | A. Srivastava | Vikash Kumar | S. Jain | A. Srivastava | Govardhan Hb | Anand Srivastava
[1] R. Arriagada,et al. Astro plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients , 1991 .
[2] R K Ten Haken,et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. , 1994, International journal of radiation oncology, biology, physics.
[3] J. Herndon,et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.
[4] J A Purdy,et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.
[5] W. Curran,et al. Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .
[6] Y. Bang,et al. A Phase III Randomized Trial of Combined Chemoradiotherapy Versus Radiotherapy Alone in Locally Advanced Non–Small-Cell Lung Cancer , 2002, American journal of clinical oncology.
[7] Di Yan,et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. , 2003, International journal of radiation oncology, biology, physics.
[8] J. Hayman,et al. NTCP modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer (NSCLC) , 2004 .
[9] Joos V Lebesque,et al. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. , 2005, International journal of radiation oncology, biology, physics.
[10] Jeffrey Bradley,et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.
[11] R. T. Ten Haken,et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. , 2005, International journal of radiation oncology, biology, physics.
[12] R. T. Ten Haken,et al. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] Randall K Ten Haken,et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.
[14] J. Lebesque,et al. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.
[15] Slav Yartsev,et al. Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. , 2007, International journal of radiation oncology, biology, physics.
[16] W. Curran,et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs): A1-05 , 2007 .
[17] George Starkschall,et al. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. , 2007, International journal of radiation oncology, biology, physics.
[18] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[19] John Wong,et al. Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. , 2009, International journal of radiation oncology, biology, physics.
[20] S. Senan,et al. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. , 2009, International journal of radiation oncology, biology, physics.
[21] Matthias Guckenberger,et al. Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer. , 2011, International journal of radiation oncology, biology, physics.
[22] Xiuping Ding,et al. Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[23] W. Curran,et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. , 2013 .